Effect on transmission of HIV-1 resistance of timing of implementation of viral load monitoring to determine switches from first to second-line antiretroviral regimens in resource-limited settings

AIDS

Volumn 25, Issue 6, 2011, Pages 843-850

  Phillips, Andrew N ^a   Pillay, Deenan ^a   Garnett, Geoff ^b   Bennett, Diane ^c   Vitoria, Marco ^d   Cambiano, Valentina ^a   Lundgren, Jens ^e  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d UNAIDS   (Switzerland)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

clinical monitoring; drug resistance; models; resource limited settings; transmission; transmitted drug resistance; treatment monitoring; viral load; virological monitoring

Indexed keywords

ANTIRETROVIRUS AGENT;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; DRUG MONITORING; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MORTALITY; PREDICTIVE VALUE; PRIORITY JOURNAL; RESOURCE MANAGEMENT; SCALE UP; STOCHASTIC MODEL; VIRUS LOAD; VIRUS TRANSMISSION;

ADULT; AFRICA SOUTH OF THE SAHARA; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; COMPUTER SIMULATION; DECISION MAKING, COMPUTER-ASSISTED; DRUG MONITORING; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; TIME FACTORS; VIRAL LOAD;

EID: 79953731323     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328344037a     Document Type: Article

References (44)

1. UNAIDS. Towards universal access. Scaling up priority HIV/AIDS interventions in the health sector. Progress Report 2009. www.unaids.org.
2. WHO, Department of HIV/AIDS. Towards universal access. Scaling up priority HIV/AIDS interventions in the health sector. June 2008 progress report. http://www.who.int/hiv.
3. Pujades-Rodríguez M, O'Brien D, Humblet P, Calmy A. Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières. AIDS 2008; 22: 1305-1312.
4. WHO, HIV Department. Prioritizing second-line antiretroviral drugs for adults and adolescents: a public health approach. Report of a WHO working group meeting. 2007 http://www.who.int/hiv/pub/meetingreports/Second-Line- Antiretroviral.pdf.
5. WHO. Antiretroviral therapy for adults and adolescents. Recommendations for a public health approach. 2006. http://www.who.int/hiv/pub/guidelines/ artadultguidelines.pdf.
6. WHO. Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents. Nov 30, 2009. http://www.who.int/hiv/pub/arv/advice/en/index.html.
7. DART Trial team. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised noninferiority trial. Lancet 2010; 375:123-131.
8. Elliott JH, Lynen L, Calmy A, De Luca A, Shafer RW, Zolfo M, et al. Rational use of antiretroviral therapy in low-income and middle-income countries: optimizing regimen sequencing and switching. AIDS 2008; 22:2053-2067.
9. Coutinho A, Mermin J, Ekwaru J, Were W, Bunnell R, Kaharuza F, et al. Utility of routine viral load, CD4 cell count, and clinical monitoring among HIV-infected adults in Uganda: a randomized trial. In: 15th Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA; 3-6 February 2008. p. 125 (abstract).
10. Phillips AN, Pillay D, Miners A, Bennett D, Gilks CF, Lundgren JD. Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model. Lancet 2008; 371:1443-1451. (Pubitemid 351635534)
11. Moore DM, Mermin J. Monitoring antiretroviral failure in resource-poor settings. Lancet 2008; 371:1396-1397. (Pubitemid 351611658)
12. Lawn SD, Bekker LG, Calmy A, Wood R. Monitoring of antiretroviral therapy in low-resource settings. Lancet 2008; 372: 287-288. (Pubitemid 352037426)
13. Calmy A, Ford N, Hirschel B, Reynolds SJ, Lynen L, Goemaere E, et al. HIV viral load monitoring in resource-limited regions: optional or necessary? Clin Infect Dis 2007; 44:128-134.
14. Gupta RK, Hill A, Sawyer AW, Cozzi-Lepri A, von Wyl V, Yerly S, et al. Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet 2009; 9:409-417.
15. Hosseinipour MC, van Oosterhout JJG, Weigel R, Phiri S, Kamwendo D, Parkin N, et al. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS 2009:231127-231134.
16. Sawe FK, McIntyre JA. Monitoring HIV antiretroviral therapy in resource-limited settings: time to avoid costly outcomes. Clin Infect Dis 2009; 49:463-465.
17. Wilson D, Keiluhu AK, Kogrum S, Reid T, Seriratana N, Ford N, et al. HIV-1 viral load monitoring: an opportunity to reinforce treatment adherence in a resource-limited setting in Thailand. Trans Roy Soc Trop Med Hygiene 2009; 103:601-606.
18. Smith DM, Schooley RT. Running with scissors: using antiretroviral therapy without monitoring viral load. Clin Infect Dis 2008; 46:1598-1600. (Pubitemid 351706743)
19. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 1 December 2009. pp. 1-161. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
20. Gazzard BG, on behalf of the BHIVA Treatment Guidelines Writing Group. British HIV Association guidelines for the treatment of HIV infected adults with antiretroviral therapy 2008. HIV Med 2008; 9:563-608.
21. Leelawiwat W, Young NL, Chaowanachan T, Ou CY, Culnane M, Vanprapa N, et al. Dried blood spots for the diagnosis and quantification of HIV-1: stability studies and evaluation of sensitivity and specificity for the diagnosis of infant HIV-1 infection in Thailand. J Vir Meths 2009; 15:109-117.
22. Marconi A, Balestrieri M, Comastri G, Pulvirenti FR, Gennari W, Tagliazucchi S, et al. Evaluation of the Abbott real-time HIV-1 quantitative assay with dried blood spot specimens. Clin Microbiol Infect 2009; 15:93-97.
23. Monleau M, Montavon C, Laurent C, Segondy M, Montes B, Delaporte E, et al. Evaluation of different RNA extraction methods and storage conditions of dried plasma or blood spots for HIV-1 RNA quantification and PCR amplification for drug resistance testing. J Clin Microbiol 2009; 47:1107-1118.
24. Point of care VL tests. http://nciia.org/node/110.
25. UNITAID. Viral load testing in low resource settings. www.unitaid.eu/en/Requests-for-proposals.html.
26. Kantor R, Shafer RM, Follansbee S, Taylor J, Shilane D, Hurley L, et al. Evolution of resistance to drugs in HIV-1 infected patients failing antiretroviral therapy. AIDS 2004; 18:1503-1511. (Pubitemid 39037474)
27. Cozzi-Lepri A, Phillips AN, Martinez-Picado J, Monforte AD, Katlama C, Hansen ABE, et al. Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine: implications for antiretroviral therapy programs in resource-limited settings. J Infect Dis 2009; 200:687-697.
28. Blower S, Bodine E, Kahn J, McFarland W. The antiretroviral rollout and drug-resistant HIV in Africa: insights from empirical data and theoretical models. AIDS 2005; 19:1-14.
29. Blower S, Ma L, Farmer P, Koenig S. Predicting the impact of antiretrovirals in resource-poor settings: preventing HIV infections whilst controlling drug resistance. Curr Drug Targets Infect Disord 2003; 3:345-353. (Pubitemid 38016622)
30. Vardavas R, Blower S. The emergence of HIV transmitted resistance in Botswana: 'when will the WHO detection threshold be exceeded?'. PLoS ONE 2007; 2:e152.
31. Smith RJ, Okano JT, Kahn JS, Bodine EN, Blower S. Evolutionary dynamics of complex networks of HIV drug-resistant strains: the case of San Francisco. Science 2010; 327:697-701.
32. Baggaley RF, Garnett GP, Ferguson NM. Modelling the impact of antiretroviral use in resource-poor settings. PLOS Med 2006; 3:e124.
33. Baggaley RF, Ferguson NM, Garnett GP. The epidemiological impact of antiretroviral use predicted by mathematical models: a review. Emerg Themes Epidemiol 2005; 2:9.
34. Abbas UL, Anderson RM, Mellors JW. Potential impact of antiretroviral therapy on HIV-1 transmission and AIDS mortality in resource-limited settings. JAIDS 2006; 41:632-641.
35. Phillips AN, Sabin CA, Pillay D, Lundgren JD. HIV in the UK 1980-2006: reconstruction using a model of HIV infection and the effect of antiretroviral therapy. HIV Med 2007; 8:536-546.
36. Bansi LK, Sabin C, Delpech V, Hill T, Fisher M, Walsh J, et al., for the UK CHIC Study Steering Committee and the Health Protection Agency. Trends over calendar time in antiretroviral treatment success and failure in HIV clinic populations. HIV Med 2010; 11:432-438.
37. Blower SM, Dowlatabadi H. Sensitivity and uncertainty analysis of complex models of disease transmission: an HIV model, as an example. Int Statist Rev 1994; 62:229-243.
38. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342:921-929. (Pubitemid 30177052)
39. Phillips AN, van Oosterhout J. DART points the way for antiretroviral treatment programmes. Lancet 2010; 375:96-98.
40. WHO AIDS Diagnostic and Medicine Service, Transaction prices for antiretroviral medicines and HIV diagnostics from 2008 to April 2009. A summary report from the Global Price Reporting Mechanism (http://www.who.int/hiv/amds/ GPRMsummaryReportJune2009.pdf).
41. Mee P, Fielding K, Charalambous S, Churchyard GJ, Grant AD. Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa. AIDS 2008; 22:1971-1977.
42. Lynen L, An S, Koole O, Thai S, Ros S, De Munter P, et al. An algorithm to optimize viral load testing in HIV-positive patients with suspected first-line antiretroviral therapy failure in Cambodia. J Acquir Immune Defic Syndr 2009; 52:40-48.
43. Kantor R, Diero L, DeLong A, Kamle L, Muyonga S, Mambo F, et al. Misclassification of first-line antiretroviral treatment failure based on immunological monitoring of HIV infection in resource-limited settings. Clin Infect Dis 2009; 49:454-462.
44. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JMAH, Miller MD, et al. Efficacy and safety of tenofovir DF vs. stavuldine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. J Am Med Assoc 2004; 292:191-201. (Pubitemid 38917996)